Concord Drugs Limited (BOM:538965)
India · Delayed Price · Currency is INR 67.93
-2.07 (-2.96%)
At close: Jul 27, 2026
Concord Drugs Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | 7.51 | 2.25 | 1.76 | 0.99 | 0.65 |
Cash & Short-Term Investments | 7.51 | 2.25 | 1.76 | 0.99 | 0.65 |
Cash Growth | 232.96% | 27.78% | 77.46% | 51.99% | 15.81% |
Accounts Receivable | 243.82 | 136.05 | 127.29 | 158.1 | 228.59 |
Receivables | 243.82 | 136.05 | 127.29 | 158.1 | 228.59 |
Inventory | 255.16 | 252.69 | 229.23 | 200.65 | 174.9 |
Other Current Assets | 26.64 | 16.63 | 16.89 | 74.82 | 14.77 |
Total Current Assets | 533.12 | 407.62 | 375.18 | 434.56 | 418.91 |
Property, Plant & Equipment | 133.69 | 135.69 | 126.67 | 132.04 | 138.83 |
Long-Term Investments | 7.83 | 8 | 8.41 | 8.94 | - |
Long-Term Accounts Receivable | - | 92.93 | 70.97 | - | - |
Other Long-Term Assets | 74.25 | 7.19 | 6.84 | 6.77 | 6.71 |
Total Assets | 748.88 | 651.42 | 588.06 | 582.31 | 564.45 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Accounts Payable | 70.71 | 76.22 | 31.01 | 52.72 | 71.79 |
Accrued Expenses | - | 2.42 | 5.37 | 6.17 | 8.81 |
Short-Term Debt | 117.93 | 158.68 | 159.49 | 142.26 | 139.52 |
Current Portion of Long-Term Debt | 9.09 | 20.51 | 9.25 | 8.27 | 7.88 |
Current Income Taxes Payable | 4.13 | 2.06 | 2.23 | 3.81 | 6.71 |
Other Current Liabilities | 8.81 | 1.91 | 2.7 | 2.91 | 1.77 |
Total Current Liabilities | 210.68 | 261.8 | 210.05 | 216.15 | 236.47 |
Long-Term Debt | 18.06 | 13.24 | 6.45 | 19.11 | 16.95 |
Pension & Post-Retirement Benefits | - | 7.6 | 5.7 | 4.75 | 0.95 |
Long-Term Deferred Tax Liabilities | 6.24 | 6.26 | 4.73 | 5.37 | 6.59 |
Other Long-Term Liabilities | 28.76 | 21.38 | 22.95 | 19.89 | 19.89 |
Total Liabilities | 263.74 | 310.28 | 249.89 | 265.27 | 280.85 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Common Stock | 131.75 | 100 | 100 | 93.16 | 87.44 |
Additional Paid-In Capital | - | 85.89 | 85.89 | 70.15 | 57 |
Retained Earnings | - | 151.14 | 148.19 | 143.99 | 135.07 |
Comprehensive Income & Other | 353.39 | 4.1 | 4.1 | 9.75 | 4.1 |
Shareholders' Equity | 485.14 | 341.14 | 338.18 | 317.04 | 283.61 |
Total Liabilities & Equity | 748.88 | 651.42 | 588.06 | 582.31 | 564.45 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Total Debt | 145.08 | 192.44 | 175.19 | 169.65 | 164.34 |
Net Cash (Debt) | -137.58 | -190.18 | -173.42 | -168.65 | -163.69 |
Net Cash Growth | - | - | - | - | - |
Net Cash Per Share | -12.39 | -19.02 | -17.34 | -18.11 | -18.72 |
Filing Date Shares Outstanding | 11.23 | 10 | 10 | 8.74 | 8.74 |
Total Common Shares Outstanding | 11.23 | 10 | 10 | 8.74 | 8.74 |
Working Capital | 322.44 | 145.82 | 165.13 | 218.42 | 182.44 |
Book Value Per Share | 43.18 | 34.11 | 33.82 | 36.26 | 32.44 |
Tangible Book Value | 485.14 | 341.14 | 338.18 | 317.04 | 283.61 |
Tangible Book Value Per Share | 43.18 | 34.11 | 33.82 | 36.26 | 32.44 |
Buildings | - | - | - | - | 67.6 |
Machinery | - | - | - | - | 297.22 |
Construction In Progress | - | - | - | - | 5.54 |